Back to all papers

Integrative Machine Learning Model Leveraging DCE-MRI and PSA Values for Advanced Risk Stratification in Prostate Cancer.

November 7, 2025pubmed logopapers

Authors

Panc K,Sekmen S,Gundogdu H,Basaran M,Bulbul HM,Gurun E

Affiliations (4)

  • Department of Radiology, Ministry of Health Karakoçan State Hospital, Elazığ, Turkey.
  • Department of Radiology, Ministry of Health Patnos State Hospital, Ağrı, Turkey.
  • Department of Radiology; Faculty of Medicine, Samsun University, Samsun, Turkey.
  • Department of Radiology; Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.

Abstract

Accurate grading of prostate cancer is critical for treatment strategies and risk stratification. This study aims to develop a machine learning (ML) model integrating Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) pharmacokinetic parameters with Prostate-Specific Antigen (PSA) values to predict ISUP grade metastatic risk groups. This retrospective study included 102 patients with histologically confirmed prostate cancer. DCE-MRI pharmacokinetic parameters (Ktrans, Kep, Ve, CER, MaxSlope, IAUGC) were standardized. The dataset was balanced using the Synthetic Minority Oversampling Technique and split into training, validation, and test sets. ML models, including Random Forest, were evaluated using Area Under the Curve (AUC) values. The Random Forest classifier achieved the highest performance, with an AUC of 0.92. Precision-recall analysis identified an optimal threshold of 0.3, balancing sensitivity and specificity for high-risk group detection. SHAP analysis highlighted PSA, MaxSlope, and Kep as key predictors contributing to model accuracy. Integrating DCE-MRI parameters with PSA values using ML algorithms enhances the prediction of ISUP grade metastatic risk groups. This method provides a robust tool for metastasis screening and personalized treatment in prostate cancer.

Topics

Journal Article

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.